Mimic Nature.
Amplify Medicine.

We are on a mission to make cell and gene therapy available to everyone, everywhere.

The problem

Cell and gene therapies have proven transformative clinical outcomes for expanding patient populations, but manufacturing remains bottlenecked by magnetic bio-separation technology from the 1990s.

Cell therapy remains trapped in high-cost, low-volume paradigms where economics dictate exclusivity over accessibility , with limited efficacy. Without change, cell and gene therapy remains limited to medical advancement rather than transformative healthcare shift.

5M+

Eligible Patient

Patient Access

<$50k

Production Cost

<50%

Relapse and Severe Side Effects

The benefit

Efficacy

By mimicking natural biology, we preserve true cell function and early-differentiated T-cell phenotypes—unlocking higher efficacy with fewer side effects.

Simplicity

What once required weeks, multiple reagents, and complex workflows now completes in days using a single reagent for sorting and activation, without costly consumables and downstream processes.

Compatibility

Designed to work with any cell culture infrastructure, our reagent integrates without hardware changes or proprietary system lock-in.

Efficiency

Up to 60% cost reduction and tenfold productivity gains make cell therapy commercially viable at scale.

Flexibility

We remove dependence on outdated magnetic separation technologies, giving manufacturers control over their process again.

The solution

DACS™ bioseparation technology based on proprietary biomimetic buoyant lipid droplets

Universal platform compatibility working with any cell type and cell culture facility, allowing manufacturing optimization across hardware systems rather than proprietary equipment lock-in leveling gravity based bioseparation.

Biological process fidelity reproducing natural immune synapse activation, preserving cellular functionality leveraging lipid droplet biomimetic.

Team